Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Organon & Co. Common Stock (NY:OGN)

14.72 +0.59 (+4.18%)
Official Closing Price Updated: 6:30 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Organon & Co. Common Stock

< Previous 1 2 3 4 5 6 7 Next >
A Look Back at Branded Pharmaceuticals Stocks’ Q4 Earnings: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Pack
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Collegium Pharmaceutical... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Unpacking Q4 Earnings: Pfizer (NYSE:PFE) In The Context Of Other Branded Pharmaceuticals Stocks
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Pfizer (NYSE:PFE) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
3 Small-Cap Stocks Skating on Thin Ice
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
Earnings Scheduled For February 13, 2025
Via Benzinga
Looking Into Organon's Recent Short Interest
Via Benzinga
P/E Ratio Insights for Organon
Via Benzinga
3 Cheap High Dividend Stocks For Passive Income
These undervalued high yield stocks could return over 10% per year. 
Via Talk Markets
1 Healthcare Stock with Solid Fundamentals and 2 to Turn Down
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Q4 Earnings Highs And Lows: Royalty Pharma (NASDAQ:RPRX) Vs The Rest Of The Branded Pharmaceuticals Stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Royalty Pharma (NASDAQ:RPRX)... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Corcept (NASDAQ:CORT) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
High Dividend 50: Organon & Co.
Organon & Co.’s current annual dividend is $1.12 per share. At around $20 per share, Organon stock has a high yield of 5.4%. 
Via Talk Markets
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields
Via Benzinga
High-Yield Healthcare: 3 Stocks With Strong Dividends
This article covers three healthcare stocks that offer dividend yields of at least 7% and dives deeper into the fundamentals to determine if they're good buys. 
Via MarketBeat
Organon (OGN) Shares Skyrocket, What You Need To Know
Shares of pharmaceutical company Organon (NYSE:OGN) jumped 12.5% in the morning session after the company reported fourth-quarter 2024 results that topped analysts' revenue and EPS expectations. While... 
Via StockStory
Topics Initial Public Offering
Exposures Securities Market
Organon (NYSE:OGN) Exceeds Q4 Expectations But Full-Year Sales Guidance Misses Expectations Significantly
Pharmaceutical company Organon (NYSE:OGN) reported Q4 CY2024 results exceeding the market’s revenue expectations, but sales were flat year on year at $1.59 billion. On the other hand, the company’s... 
Via StockStory
Organon (OGN) Q4 Earnings Report Preview: What To Look For
Pharmaceutical company Organon (NYSE:OGN) will be reporting earnings tomorrow before market hours. Here’s what investors should know. 
Via StockStory
Want $2,000 in Annual Dividends? Invest $11,000 in Each of These 3 Stocks.
Via The Motley Fool
Want $300 in Dividends Every Month? Invest $20,000 in Each of These 3 Stocks
These dividend stocks all pay yields of around 6% and higher. 
Via The Motley Fool
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4
Via Benzinga
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Organon, Howmet Aerospace And More: CNBC's 'Final Trades'
On CNBC's "Halftime Report Final Trades," Stephen Weiss of Short Hills Capital Partners named ProShares Short QQQ as his final trade. 
Via Benzinga
Week In Review: Nippon Shinyaku Signs $735 Million Deal For DMD Therapy
Japan’s Nippon Shinyaku will acquire European rights for a Duchenne muscular dystrophy disease therapy developed by Capricor Therapeutics of San Diego. Nippon Shinyaku will pay $20 million upfront and... 
Via Talk Markets
Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B
Organon is set to acquire Roivant Sciences' Dermavant Sciences, known for developing immuno-dermatology treatments, including FDA-approved Vtama cream for plaque psoriasis. The deal, valued up to $1.2... 
Via Benzinga
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva, Organon, and Viatris. 
Via Benzinga
Organon Stock Sees Relative Strength Rating Rise To 91
On Tuesday, Organon[ stock hit an key technical milestone, seeing its Relative Strength Rating jump to 91, up from 88 the day before. 
Via Investor's Business Daily
Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold
On Tuesday, generic drug maker Organon stock had its Relative Strength (RS) Rating upgraded to 83, up from 78 a day earlier. 
Via Investor's Business Daily
OGN Stock Earnings: Organon Beats EPS, Misses Revenue for Q2 2024
OGN stock results show that Organon beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Jim Cramer Says No To This Health Care Stock, Recommends Holding On To Constellation Energy: 'It's Up A Huge Amount'
Jim Cramer said Constellation Energy is a "solar play that is a very good company. It's up a huge amount versus a lot of other stocks." 
Via Benzinga
3 High-Yield Dividend ETFs to Buy to Generate Passive Income
These exchange-traded funds should keep the income flowing in regularly. 
Via The Motley Fool
Topics ETFs
Value Investing Is Back! 3 Stocks With Strong Fundamentals to Buy Now
Uncover three top value stocks to buy with robust fundamentals for stable long-term growth amid turbulence. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.